QatarPRNetwork.com, Online Press Release from Qatar and Doha City
 
(Business and Economy)
Filter PR by
  
 
WCM-Q students probe the effects of weight loss drugs on diabetes, obesity and cancer

Doha – July 17, 2024: Students at Weill Cornell Medicine-Qatar (WCM-Q) have made a significant contribution to the field by publishing a study that delves into the effects of Ozempic-type drugs on the interconnected health challenges of obesity, diabetes, and cancer.

Ozempic, the brand name of a drug called semaglutide, belongs to a class of medications called glucagon-like peptide-1 receptor (GLP-1R) agonists. These medications have recently become extremely well-known as treatments for managing obesity and diabetes by helping to control feelings of hunger, reduce food consumption, and promote weight loss.

Beyond the effects on hunger, however, the underlying mechanisms of GLP-1R agonists are believed to have a multifaceted impact on cancer progression -- some studies show that some drugs in the class can limit cancer growth. In contrast, other studies suggest that some GLP-1R agonists may be associated with increased cancer risk. This ambiguity prompted WCM-Q students Shahad Sabaawi Ibrahim, Raghad Sabaawi Ibrahim, and Batoul Arabi to conduct a comprehensive literature review of existing research into the effects of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer to help clarify the effects of this newly popular class of medications.

Under the supervision and guidance of Dr. Dietrich Büsselberg, associate dean for admissions/professor of physiology and biophysics, the students noted that some studies show that GLP-1R agonists such as semaglutide help address type 2 diabetes by helping to control glucose levels and promoting insulin release. Beyond this, semaglutide helps regulate blood glucose levels by reducing hunger, moderating food intake, and managing body weight. Furthermore, GLP-1R agonists have been shown to inhibit cancer progression of some tumors.

However, the students urge caution, pointing to other studies that appear to show that semaglutide is associated with increased neoplasm (abnormal and excessive tissue growth) and increased tumorigenesis, specifically in thyroid, bladder, colorectal, and pancreatic cancer. The study notes that pharmaceutical companies have issued a warning about the use of semaglutide for patients with thyroid cancer or increased risk of developing it. Also, it states that there is no conclusive evidence that semaglutide induced cancer development in tissue. Furthermore, some studies reported mitigation of cancer proliferation in patients treated with semaglutide. 

Raghad said: 'Our review underscores the extreme complexity of the metabolic processes that underpin the relationship between obesity, diabetes mellitus and cancer. Our study suggests that introducing GLP-1R agonists like semaglutide, which interact with and alter these intricate metabolic processes, adds another layer of complexity, thus producing contradictory and somewhat unpredictable side effects in terms of the impact on cancer risk and cancer progression.'

Shahad said: 'This review found that GLP-1R agonists such as semaglutide have been found to be associated with both the proliferation and mitigation of cancerous cells. Our conclusion therefore calls for more research to improve understanding of the effects of semaglutide and other GLP-1R agonists on cancer.'

Researchers Aranka Brockmueller, Mehdi Shakibaei and Dr. Büsselberg contributed to the study. The paper, titled 'The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer,' has been published in the highly regarded journal Cancer and Metastasis Reviews. 


Posted by : Qatar and Doha City PR Network Editorial Team
Viewed 2958 times
PR Category : Business and Economy
Posted on : Monday, January 13, 2025  12:00:00 AM UAE local time (GMT+4)
Replication or redistribution in whole or in part is expressly prohibited without the prior written consent of QatarPRNetwork.com.
Previous Story : LG Releases Second-Quarter 2024 Financial Results
Next Story : MEEZA and AMD Announce Strategic Cooperation Agreement to Ac...
Email this article Print this article

Share this article with your friends and followers
NewsVine
Most Viewed Press Release posted in the last 7 days
Extreme Lashes, Extreme Style: essence Goes Bold and Blue for the New Year [47923-Views]
Get Ready to Shine – Catrice Drops the Melt & Shine Juicy Lip Balms [45936-Views]
Scent-sational Gifting: Top 5 Ajmal Perfumes to Celebrate the Holidays [40573-Views]
Turkish Airlines Sets Guinness World Records™ title for the “Most Countries Flown to by an Airline” [37209-Views]
Benefit Cosmetics is revealing its New Brow product: Mighty Fine Brow Pen [34495-Views]
CASIO celebrates 50-year-long watchmaking heritage with exclusive anniversary collection [30311-Views]
Essence Unveils Kingdom of Essentia: A New Era of Immersive Experiences in the Roblox Metaverse [28202-Views]
Get the Look: Cynthia Erivo's Golden Globes Glam by Benefit Cosmetics [27674-Views]
TONDA PF XIALI CHINESE CALENDAR [25061-Views]
Benefit Cosmetics unveils its new mascara innovation: BADgal Bounce Mascara! [24580-Views]
Catrice's Hottest Bestsellers in MENA – Flawless, Vegan & Affordable Beauty [24174-Views]
LVMH WATCH WEEK 2025 [23747-Views]
SHOOTING ON WFP CONVOY IN GAZA [23451-Views]
Introducing the pinnacle of craftsmanship and innovation: MRG-B2000JS and MTG-B2000YST [23246-Views]
Mesmerizing Shows and Cash Prizes at Mercato During Dubai Shopping Festival [23029-Views]
Mercato Announces DSF Cash Prize Winners and Gets Ready for the Grand Prize Car Draw! [22866-Views]
Porsche achieves sustainable growth of four percent across the region in 2024 [22727-Views]
SalamAir Releases 4th Quarter (Q4) On-Time Performance Data [21787-Views]
Air Cargo Demand up 8.2% in November 2024 - 16th Month of Consecutive Growth [21029-Views]
Global Air Cargo Demand Achieves Record Growth in 2024 [20963-Views]
Back to Section Home

Related Stories



 
Top Sections